作者
Jeanne Tie, Isaac Kinde, Yuxuan Wang, Hui-Li Wong, Justin Roebert, Michael Christie, Mark Tacey, R Wong, M Singh, CS Karapetis, Jayesh Desai, Ben Tran, Robert L Strausberg, Luis Alberto Diaz Jr, Nickolas Papadopoulos, Kenneth W Kinzler, B Vogelstein, Peter Gibbs
发表日期
2015/8/1
期刊
Annals of Oncology
卷号
26
期号
8
页码范围
1715-1722
出版商
Elsevier
简介
Background
Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy.
Patients and methods
This prospective study involved 53 mCRC patients receiving standard first-line chemotherapy. Both ctDNA and CEA were assessed in plasma collected before treatment, 3 days after treatment and before cycle 2. Computed tomography (CT) scans were carried out at baseline and 8–10 weeks and were centrally assessed using RECIST v1.1 criteria. Tumors were sequenced using a panel of 15 genes frequently mutated in mCRC to identify candidate mutations for ctDNA analysis. For each patient, one tumor mutation was selected to assess the presence and the level of ctDNA in plasma samples using a digital genomic assay termed Safe-SeqS.
Results …
学术搜索中的文章
J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie… - Annals of Oncology, 2015